Genome Editing Therapeutics Summit on September 29-October 01, 2025 in Boston, United States

Welcome to the 6th Genome Editing Therapeutics Summit

2025 has been industry-defining for the genome editing space. With baby KJ successfully receiving the world's first personalized CRISPR therapy, alongside continued innovation across in vivo and base editing, and rapid ex vivo clinical progress, the field stands at a pivotal juncture, ready to unlock the transformative potential of both established assets, and cutting-edge breakthroughs.

In an effort to capture this excitement, spotlight innovation and propel clinical progress, the 6th Genome Editing Therapeutics Summit returns to Boston. Addressing challenges and advancements in the application and delivery of novel gene editing technologies, including base, prime, multiplex, epigenome editing and more, this forum serves as your lens into the future of genome editing.

Showcasing both clinical advances and cutting-edge technologies from Metagenomi, Editas Medicine, University of Pennsylvania, nChromaBio, and Beam Therapeutics, this meeting will provide you with the critical learnings needed to optimize safety and durability, while building a robust clinical strategy to fast-track best-in-class therapeutics to more patients in need.

URLs:

Tickets: https://go.evvnt.com/3110473-2?pid=10008

Brochure: https://go.evvnt.com/3110473-3?pid=10008

Time: 8:30 AM - 5:15 PM

Prices:

Conference + Workshop Day - Drug Developer Pricing: USD 4197.00,

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + Workshop Day - Academic Pricing: USD 3597.00,

Conference Only - Academic Pricing: USD 2599.00,

Conference + Workshop Day - Solution Provider Pricing: USD 5097.00,

Conference Only - Solution Provider Pricing: USD 3699.00

Speakers: Adam Garskem Director - Protein Engineering, Mammoth Biosciences, Alexandria Petrusich, Vice President, Clinical Science, Prime Medicine, Anna Pugh, Scientist, Tune Therapeutics, Anubhav Arora, Director - Chemistry, Manufacturing, and Controls, Apellis Pharmaceuticals, Brad Ringeisen, Executive Director, Innovative Genomics Initiative, Carlo Zambonelli, Principal, Zambonelli Consulting, Chris Brown, Vice President - Discovery, Metagenomi, Dan Hart, Head of Technology Development, Epic Bio, Daniel Dornbusch, Chief Executive Officer, Excision BioTherapeutics Inc., Greg Newby, Assistant Professor, Johns Hopkins University, Johnathan Finn, Chief Scientific Officer, Basecamp Research, Kiran Musunuru, Professor - Translational Research, University of Pennsylvania, Matteo Gentili, Senior Scientist, nChroma Bio, Michael Sherman, Principal, Sherman Health Systems, Nageswara Kollu, Senior Director Gene Therapy, Apellis Pharmaceuticals, Niren Murthy, Professor, University of California at Berkeley, Priya S. Chockalingam, Vice President, Head, Clinical Bioanalytics and Translational Sciences, Beam Therapeutics , Ralf Schmid, Associate Director, Preclinical Research, Novartis AG, Rammohan Devulapally, Director, Non-Viral delivery, Independent Expert, TJ Cradick, Chief Technology Officer, HuidaGene Therapeutics, Yi Yu, Senior Director- Platform Technologies, nChroma Bio, Yonatan Lipsitz, Chief Executive Officer, Lilium Therapeutics, Yosuke Nakashima, Vice President and Executive Officer - Operations and Business Development, Modalis Therapeutics